Hormonal
Insulin-like Growth Factor-I (IGF-I) administration ameliorates liver fibrosis and NASH by inducing cellular senescence in hepatic stellate cells (HSCs), thereby inactivating them and limiting fibrosis progression.
IGF-I shows promise in animal studies for reversing liver scarring (fibrosis) by putting the scar-forming cells into a state of 'senescence' where they stop working. While not yet a standard human treatment, it represents a potential future therapy for advanced liver disease.
IGF-I induces cellular senescence and inactivates hepatic stellate cells, therefore ameliorating fibrosis.
Why this rating
Strong evidence in animal models (mice, rats) and some human observational data, but limited human clinical trials for IGF-I specifically for fibrosis.
Source
The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver
Yutaka Takahashi · International Journal of Molecular Sciences · 2017
DOI 10.3390/ijms18071447
More from this paper
- Low serum levels of IGF-I are associated with the severity of NAFLD, including inflammation, hepatocyte ballooning, and fibrosis, even in non-GHD patients.Good
- Growth hormone (GH) replacement therapy in adults with growth hormone deficiency (GHD) improves non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) by reducing visceral adipose tissue and directly decreasing hepatic lipogenesis.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →